Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,612.82
(
-0.18%
)
US TECH 100
23,734.40
(
-0.26%
)
Dow Jones
46,114.09
(
-0.24%
)
Brent Oil
103.40
(
-2.98%
)
Bitcoin
70,446.84
(
-1.12%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: pcrutch post# 146406

Wednesday, 08/01/2012 7:00:52 PM

Wednesday, August 01, 2012 7:00:52 PM

Post# of 257259

After reviewing the data, CDER has confirmed that there is no need for actions against Hylenex or clinical programs in the Hylenex IND.



Why is this worse? CDER doesn't find a need to suspend approved product Hylenex after reviewing the non-neutralizing antibody data. To me it shows this is pre-caution by CBER rather than alarming non-neutralizing antibody data that caused CBER's decision.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now